Kromek Group PLC (LON:KMK) achieved significant revenue growth during the second half of the 2021 financial year, as orders and shipments of the company’s medical, nuclear and security screening detection technology resumed in the final two months of the first half of the year.
As such the company entered the second half with an extensive commercial pipeline and experienced increased commercial activity. This momentum continued throughout the second half as Kromek delivered on previously awarded contracts and won new orders.
The company expects to report revenue and EBITDA for the year ended 30 April 2021 in line with market expectations. Tight cost control, improved collections and well-managed cash flow has resulted in the cash position at 30 April 2021 being slightly ahead of market expectations.
During the second half of the year, Kromek commenced piloting its airborne COVID-19 detection solution at an airport and at another public place.